

Madrid, March 19, 2026

LABIANA HEALTH, S.A. (hereinafter, the “Company”), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, and in accordance with the provisions of Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, regarding information to be provided by companies listed for trading on said segment, hereby announces the following:

### **OTHER RELEVANT INFORMATION**

#### **Resolutions of the General Shareholders’ Meeting**

At the Company’s Extraordinary General Shareholders’ Meeting held on March 20, 2026, at 11:00 a.m., on first call, in Madrid, at the Company’s registered office located at Av. Europa, 34D, 28023 Pozuelo de Alarcón (Madrid), with attendance, in person or by proxy, shareholders representing 90.1% of the Company’s share capital, all of the proposed resolutions submitted to the General Meeting for approval were unanimously approved.

In compliance with the provisions of Circular 3/2020 of the BME MTF Equity, it is hereby expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its directors.

We remain at your disposal for any clarifications you may require.

Sincerely,

Mr. Manuel Ramos Ortega  
Chief Executive Officer  
LABIANA HEALTH, S.A.

**LABIANA HEALTH, S.A.**

**Resolutions Approved by the 2025 Annual General Meeting of Shareholders**

The following is a transcript of the resolutions approved by the Ordinary General Shareholders' Meeting of LABIANA HEALTH S.A., held on March 20, 2026, on first call, as well as the voting results.

**Agenda**

**Item 1. Acknowledgment and ratification of the Company's financing transaction, for a maximum amount of up to thirty-seven million euros (€37,000,000).**

**Item 1. Ratification of the financing transaction**

To ratify the syndicated financing transaction entered into by the Company for a maximum amount of up to 37,000,000 euros, granted on a syndicated basis by Deutsche Bank (Lead Arranger and Agent), Caixabank, Banco Santander, Andbank, and ICF, as well as the cancellation of the existing financing granted by Miralta Credit Opportunities, S.L. and BSSF II Origination DAC, and the guarantees associated therewith.

Likewise, the execution and implementation of the documents related to said transaction are hereby ratified, including the financing agreement, the guarantee documents, and any other documents necessary for its implementation, all in the best interests of the Company and the Group.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

**Item 2.- Authorization and waiver regarding self-dealing and conflicts of interest**

To authorize the Company's directors and authorized representatives to execute and formalize all acts and documents necessary in connection with the financing transaction.

Likewise, expressly waive any situations of self-dealing, multiple representation, or conflict of interest that may arise from said transaction, and ratify the actions previously taken in this context.

- Votes in favor: 100%
  - Votes against: 0%
  - Abstentions: 0%
-

**Item 3.- Delegation of Powers and Notarization**

To delegate to the directors and to the persons designated for that purpose the powers necessary for the formalization, execution, interpretation, rectification, and notarization of the resolutions adopted by the Meeting.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%